secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-115285
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical reports Q3 2023 net income of $16.8M vs loss a year ago; revenue up 114% YoY to $34.5M
--------------------------------------------------------------------------------

- GAAP net income $16.8M ($0.80 diluted) vs GAAP net loss $10.1M in Q3 2022.
- Total net revenue $34.5M, +114% YoY, including $19.0M upfront from Maruho license for Qbrexza in Asia.
- Adjusted EBITDA $20.8M ($0.99 diluted) vs -$4.0M in Q3 2022.
- Cost reduction to cut annual SG&A >$17M, surpassing prior $12M target; Q3 SG&A fell 45% to $8.6M.
- DFD-29 NDA for rosacea expected to be submitted to FDA around year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/0001104659-23-115285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/tm2330064d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer